The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Notice of AGM and Annual Report 2021

1 Apr 2022 07:00

RNS Number : 8365G
Belluscura PLC
01 April 2022
 

 

Belluscura plc

("Belluscura" or the "Company" or "Group")

 

 Notice of AGM and Annual Report 2021

 

LONDON, U.K. AND PLANO, TX, U.S. (1 April 2022). Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the Notice of Annual General Meeting ("Notice") is being posted shareholders today and will shortly be available on the Company's website at: https://investors.belluscura.com/investors/shareholder-information.

 

The Annual Report and Accounts for the year ended 31 December 2021 is being posted along with the Notice and will be available on the Company's website at: https://investors.belluscura.com/investors/annual-interim-reports. 

 

If you wish to submit a proxy vote for this meeting, please submit your vote online at www.signalshares.com. For your vote to be valid please ensure that it is received by no later than 12.00 NOON on 21 April 2022. Alternatively, should you wish to vote via the CREST system, please see the instructions in the Notice. 

 

For further information please contact:

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via Walbrook PR

Anthony Dyer, Chief Financial Officer

SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com

Paul McManus / Sam Allen

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCJBMATMTJJBLT

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.